

**Current Report**

**Current Report as per** - *Art 226 of Law no. 297/2004 and Art. 113 of CNVM Regulation no. 1/2006*

**Report date:** - *31.10.2016*

**Name of issuing entity** - *S.C. ZENTIVA S.A.*

**Registered headquarters:** - *50 Theodor Pallady Blvd., Bucharest*

**Tel/fax number:** - *021-3047200 /021-345.40.04*

**Sole registration code:** - *336206*

**No. of registration with the Trade Registry:** *J/40/363/1991*

**Subscribed paid-in share capital** - *41,696,115 RON*

**Regulated market on which the issued securities are traded:** - *Bucharest Stock Exchange*

**Important event to report:**

S.C. Zentiva SA informs that on October 28, 2016, Sanofi made public, within the official communication on Q3 2016 Results, the decision to initiate a carve-out process in order to divest its Generics business in Europe, as follows:

*"As announced in our 2020 strategic roadmap, Sanofi has carefully reviewed all options and has decided to initiate a carve-out process in order to divest its Generics business in Europe. Sanofi will be looking for a potential acquirer that will leverage the mid and long-term sustainable growth opportunities for this business. Sanofi confirms its commitment to its Generics business in other parts of the world and will further focus on the Emerging Markets in order to develop its business in those countries."*

Please note that the official text of the communication can be found on Sanofi's site, Investors Section, at the link: <http://en.sanofi.com/investors/investors.aspx> .

**SC ZENTIVA SA**  
**Emmanuelle Valentin**  
*Chairman of the Board of Directors*

